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ABSTRACT 
Kynurenic acid (KYNA), an endogenous N-Methyl-D-aspartic acid receptor (NMDAR) 
antagonist, is elevated in patients with schizophrenia. In addition, elevated levels of KYNA are 
associated with activation of the immune system, which also has been implicated in the 
development and maintenance of psychotic disorders, including schizophrenia. 
The aim of this thesis was to further investigate the role of KYNA in the pathophysiology of 
schizophrenia. Thus, patients with schizophrenia were examined with respect to cerebrospinal 
fluid (CSF) levels of interleukin (IL)-6, kynurenines, and the functional effects of G protein-
coupled receptor kinase 3 (GRK3) expression. Mice administered lipopolysaccharide (LPS), 
amphetamine, or lacking the immune-regulating enzyme GRK3, were studied with respect to 
biochemical and functional aberrations associated with schizophrenia.  
The elevated CSF levels of IL-6 found in patients with schizophrenia were associated with 
increased CSF KYNA levels. Administration of IL-6 increased KYNA production in astrocytes 
and lower GRK3 expression in healthy individuals correlated to increased CSF KYNA levels. 
GRK3 was further found to be associated with psychosis in patients with bipolar disorder. 
Subchronic elevation of KYNA, or lack of GRK3 augmented the amphetamine response as 
verified by increased locomotor activity and dopamine release. Signs of amplified immune 
activity were evident in Grk3-/- mice by increases in astrocyte markers, IL-1β, kynurenine, and 
KYNA turnover. Intracerebroventricular (ICV) administration of IL-1β, and dual, bot not single 
injections of LPS increased brain KYNA. In addition, mice injected ICV with IL-1β or lacking 
GRK3 showed disrupted prepulse inhibition (PPI). 
Results presented here point to an intimate relationship between immune activation, the 
kynurenine pathway, and psychosis. Specifically, immune activation, present in patients with 
schizophrenia, was demonstrated to activate the kynurenine pathway. In addition, activation of 
the kynurenine pathway induced KYNA and lead to behavioral aberrations in rodents. 
 ii 
LIST OF SCIENTIFIC PAPERS 
 
I. Olsson, S. K., Larsson, M. K., Erhardt, S. (2012). Subchronic elevation of brain kynurenic 
acid augments amphetamine-induced locomotor response in mice. Journal of Neural 
Transmission (Vienna, Austria : 1996), 119(2), 155–163. doi:10.1007/s00702-011-0706-6 
 
II. Schwieler, L*., Larsson, M. K*., Skogh, E., Kegel, M. E., Orhan, F., Abdelmoaty, S., et al. 
(2014). Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic 
schizophrenia - significance for activation of the kynurenine pathway. Journal of Psychiatry 
& Neuroscience : JPN, 39(6), 140126. doi:10.1503/jpn.140126 
*These authors contributed equally to this work 
 
III. Carl Sellgren*, Markus Larsson*, Funda Orhan, Magdalena E Kegel, Ida Nilsson, Susan B 
Powell, S Caldwell, M Kamenski, Sarah E Bergen, Lilly Schwieler, Camilla I Svensson, Paul 
Lichtenstein, Martin Schalling, Mikael Landén, Göran Engberg, Sophie Erhardt. Targeting of 
GRK-3 identifies a molecular pathway leading to glial activation in psychotic disorders. 
Manuscript 
* These authors contributed equally to this work.  
 
IV. Larsson, M.K, Faka A, Bhat M, Goiny M, Orhan F, Oliveros A, Ståhl S, Liu XC, Choi DS, 
Sandberg K, Engberg G, Schwieler L, Erhardt S. (2015) Repeated LPS injections induce 
disparate changes in the kynurenine pathway versus a single injection - Relevance for animal 
models of psychiatric disorders. Manuscript 
 iii 
CONTENTS 
1	   Introduction ............................................................................................................................. 1	  
1.1	   Schizophrenia .............................................................................................................. 1	  
1.2	   Immunological aspects ................................................................................................ 2	  
1.2.1	   The main glial cells in the nervous system .................................................. 3	  
1.2.2	   The P2X7 receptor ........................................................................................ 3	  
1.2.3	   G-protein coupled receptor kinase 3 ............................................................ 4	  
1.3	   Kynurenic acid and schizophrenia .............................................................................. 4	  
1.3.1	   The kynurenine pathway .............................................................................. 5	  
1.3.2	   Regulation of the kynurenine pathway ........................................................ 6	  
1.4	   Animal Models of schizophrenia ................................................................................ 6	  
1.4.1	   Developmental, genetic, and lesion models ................................................. 7	  
1.4.2	   Immune models ............................................................................................ 7	  
1.5	   The dopamine and glutamate hypothesis of schizophrenia ........................................ 8	  
2	   Aims ........................................................................................................................................ 9	  
3	   Materials and methods .......................................................................................................... 10	  
3.1	   Drugs and chemicals (papers I – IV) ........................................................................ 10	  
3.2	   Astrocyte cultures (paper II) ..................................................................................... 11	  
3.3	   P2X7 internalization (paper III) ................................................................................ 12	  
3.3.1	   Separation of membrane fractions ............................................................. 12	  
3.3.2	   Western blot ................................................................................................ 12	  
3.4	   Immunohistochemistry (paper III) ............................................................................ 12	  
3.5	   Animals (papers I, III, IV) ......................................................................................... 13	  
3.6	   Tissue collection and preparation (papers I – IV) .................................................... 13	  
3.7	   Human subjects (papers II, III) ................................................................................. 14	  
3.8	   Animal surgery .......................................................................................................... 14	  
3.8.1	   Microdialysis surgery (paper III) ............................................................... 14	  
3.8.2	   Intracerebroventricular IL-1β injection (paper III) .................................... 15	  
3.9	   PPI (paper III) ............................................................................................................ 16	  
3.9.1	   Grk3 -/- mice ................................................................................................ 16	  
3.9.2	   IL-1β infused mice ..................................................................................... 17	  
3.10	   Locomotor activity (paper I) ................................................................................... 17	  
3.11	   Microdialysis (paper III) ......................................................................................... 17	  
3.12	   LPS injections (paper IV) ........................................................................................ 18	  
 iv 
3.13	   High-performance liquid chromatography (papers I – V) ..................................... 18	  
3.13.1	   Fluorescent detection (papers I – IV) ....................................................... 18	  
3.13.2	   Electrochemical detection (papers III, IV) .............................................. 18	  
3.14	   Liquid chromatography/Mass spectrometry (papers II, IV) .................................. 19	  
3.15	   Electrochemiluminescent detection (papers II, III) ................................................ 19	  
3.16	   Statistics ................................................................................................................... 20	  
3.16.1	   Paper I ....................................................................................................... 20	  
3.16.2	   Paper II ..................................................................................................... 20	  
3.16.3	   Paper III .................................................................................................... 20	  
3.16.4	   Paper IV .................................................................................................... 21	  
4	   Results and discussion .......................................................................................................... 22	  
4.1	   Paper I ........................................................................................................................ 22	  
4.1.1	   Acute kynurenine administration ............................................................... 22	  
4.1.2	   Subchronic kynurenine administration ...................................................... 22	  
4.2	   Paper II ...................................................................................................................... 24	  
4.2.1	   CSF levels of IL-6 and IL-8 in patients ..................................................... 24	  
4.2.2	   Analyses of tryptophan metabolites ........................................................... 25	  
4.2.3	   IL-6 induced production of KYNA in astrocytes ...................................... 25	  
4.3	   Paper III ..................................................................................................................... 26	  
4.3.1	   Identification of SNPs associated with schizophrenia ............................... 26	  
4.3.2	   P2X7 membrane levels in Grk3-/- mice ..................................................... 27	  
4.3.3	   Hippocampal IL-1β levels in Grk3-/- mice ................................................ 27	  
4.3.4	   ICV IL-1β administration in C57BL6 mice .............................................. 27	  
4.3.5	   PPI ............................................................................................................... 28	  
4.3.6	   Microdialysis .............................................................................................. 30	  
4.3.7	   Immunohistochemistry ............................................................................... 30	  
4.4	   Paper IV ..................................................................................................................... 33	  
5	   General Discussion ............................................................................................................... 35	  
6	   Acknowledgements ............................................................................................................... 37	  
7	   References ............................................................................................................................. 40	  
 
 v 
LIST OF ABBREVIATIONS 
3-HK 3-Hydroxykynurenine 
5-HIAA 5-Hydroxyindoleacetic acid 
5-HT 5-Hydroxytryptamine (Serotonin) 
aCSF Artificial cerebrospinal fluid 
ANOVA Analysis of variance 
ATP Adenosine triphosphate 
AUC Area under curve 
BPRS Brief Psychiatric Rating Scale 
CNS Central nervous system 
COX Cyclooxygenase 
CSF Cerebrospinal fluid 
DOPAC 3,4-Dihydroxyphenylacetic acid 
e.g. For example (exempli gratia lat.) 
EDTA Ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
GAF Global assessment of functioning 
GFAP Glial fibrillary acidic protein 
GRK3 G-protein coupled kinase 3 
GWAS Genome-wide association study 
HPLC High-performance liquid chromatography 
HVA Homovanillic acid 
i.p. Intraperitoneal 
IC50 half maximal inhibitory concentration 
ICV Intracerebroventricular 
IDO Indoleamine 2,3-dioxygenase 
IFN Interferon 
 vi 
IL Interleukin 
KAT Kynurenine aminotransferase 
KMO Kynurenine monooxygenase 
KO Knock-out 
KYNA Kynurenic acid 
LA Locomotor activity 
LPS Lipopolysaccaride 
NFκB Nuclear factor kappa B 
NMDAR N-Methyl-D-aspartic acid receptor 
P2X7 P2X purinoceptor 7 
PCA Perchloric acid 
PCP Phencyclidine (Angel dust) 
PFA Paraformaldehyde 
PPI Prepulse inhibition 
QUIN Quinolinic acid 
s.c. Subcutaneous 
SNP Single nucleotide polymorphism 
TDO Tryptophan 2,3-dioxygenase 
TLR Toll-like receptor 
α7nAChR α7 nicotinic acetylcholine receptor 
 
  1 
1 INTRODUCTION 
Hypotheses regarding the immune system as a contributor to the development of psychiatric 
disorders have been put forward since the early 1900s. However, these were at large rejected as 
the central nervous system (CNS) was believed to be an immune-privileged area. Clinical 
observations and experiments have since then dramatically changed our view of the interaction 
between the brain and the immune system. These findings have without a doubt been of great 
importance for our understanding of the human brain and may hopefully lead to more effective 
treatments for psychiatric disorders. 
1.1 SCHIZOPHRENIA 
The disorder later coined as schizophrenia by Eugene Bleuler (Bleuler, 1911) was first described 
by the german psychiatrist Emil Kraepelin in the end of the nineteenth century (Kraepelin, 1896). 
Patients that suffer from schizophrenia experience a wide range of symptoms that distort their 
sense of reality. In addition and perhaps not as recognized is the excess mortality (Saha et al., 
2007), including death by suicide that follows the disorder. 
Current studies estimate the point prevalence of schizophrenia at approximately 0.5 % (McGrath 
et al., 2008). Schizophrenia has a massive socioeconomic impact (estimated annual cost in US ~ 
$23 billion (Desai et al., 2013)), and causes an immense suffering for affected individuals and 
their relatives. Prior to the onset of the disorder, a prodromal syndrome exists when symptoms 
such as withdrawal, depression, and paranoia may present (Yung and McGorry, 1996). Efforts 
are currently being put into identifying individuals with a high risk of developing full-blown 
schizophrenia as some studies indicate that treatment may delay or prevent transition to psychosis 
(Stafford et al., 2013). The risk of developing schizophrenia peaks in late teens, after the mid-
twenties the risk declines substantially while there is a slight increase in the incidence again in 
menopausal women (Gupta et al., 2012). 
The symptoms of schizophrenia are classified into three clusters: i) positive symptoms, which 
entail symptoms that are present in the patient population, but not in healthy individuals. These 
symptoms include hallucinations and delusions. ii) negative symptoms refer to personality traits 
absent in afflicted individuals that used to be present prior to disease onset, and are also present in 
healthy individuals. These symptoms usually include anhedonia, loss of social interest, blunted 
affect, and lack of motivation. iii) cognitive symptoms refer to disturbances in thought processes 
and include but are not limited to: working and long-term memory problems and attention 
deficits. See Andreasen and Olsen, 1982 for overview of the classification system. 
Patients are usually treated with antipsychotic drugs. These were discovered in the 1950s and 
were later shown to exert their effect by blocking dopamine receptors. The contemporary arsenal 
of antipsychotic drugs quite effectively ameliorates the positive symptoms of schizophrenia. 
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However, there is still a large unmet need in the treatment of negative and cognitive symptoms, 
and it is these symptoms that to a large degree determine the level of functioning in patients 
(Tamminga et al., 1998). 
Several factors that increase the risk of developing schizophrenia have been identified. The 
strongest is family history, suggesting a major genetic influence. In support of this, it has been 
estimated that around 80% of the risk of developing schizophrenia is explained by genetic factors 
(Cannon et al., 1998; Cardno et al., 1999; Sullivan et al., 2003). Additional evidence of strong 
genetic influence is provided by twin adoption studies showing concordance rates around 50 % 
(Cardno and Gottesman, 2000). It has further been shown that there is a substantial overlap 
between risk genes for schizophrenia and bipolar disorder. Other identified risk factors include 
migration, male sex, urban living (McGrath et al., 2004), and heavy adolescent marijuana use 
(Semple et al., 2005). The prevalence, however, seems to be equal among non-developed and 
developed countries (Mellergard, 1980). 
1.2 IMMUNOLOGICAL ASPECTS 
Early evidence of immune involvement in schizophrenia comes from observations of an increase 
in the incidence of psychosis in areas affected by the influenza pandemic in 1918 (Menninger, 
1919). Prior to the introduction of antipsychotic drugs, patients with schizophrenia received pyro 
therapy (fever induction), however with mixed results as some patients deteriorated again after 
treatment (Jauregg, 1926). More recent studies show that birth in late winter may be a risk factor 
for later development of schizophrenia, possibly due to viral infections (Baron and Gruen, 1988). 
Moreover, offspring to mothers exposed to infectious agents (e.g. toxoplasma gondii, influenza, 
herpes virus) during pregnancy have an increased risk of developing psychotic disorders, 
including schizophrenia (Yolken and Torrey, 2008). Interestingly, offspring's risk of developing 
schizophrenia in adulthood has been associated with increased maternal levels of the pro-
inflammatory cytokine interleukin (IL)-8, regardless of the reason for this elevation (Brown et 
al., 2004). This points to maternal immune activation as the culprit that renders offspring 
vulnerable and not the infectious agent per se. No single immunological factor has yet been 
identified that fully explains the wide range of symptoms and pathology of schizophrenia. 
However, large genome-wide association studies (GWAS) have identified regions containing 
immune-related genes as significantly associated with schizophrenia (Shi et al., 2009). Clinical 
studies point to distinctive patterns of immune activation during different stages of the disorder 
(Miller et al., 2011). For instance, the cytokine IL-1β is increased in the cerebrospinal fluid 
(CSF) of patients with a recent onset of the disorder (Söderlund et al., 2009). As immune cells 
coordinate the immune response by the release of cytokines, increased levels of cytokines may 
thus indicate increased immune activity in these patients. 
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1.2.1 The main glial cells in the nervous system 
Previously seen as merely providing a scaffold for neurons, astrocytes have in recent years been 
recognized as important contributors to brain function. Astrocytes may reside in proximity to 
synapses, where they perform multiple duties such as neurotransmitter recycling, metabolic 
support, and regulation of ion concentrations in the extracellular space (Walz, 2000). The major 
influence of astrocytes on synaptic neurotransmission has widened the synapse concept into a 
tripartite synapse model (Araque et al., 1999). 
Microglial cells are predominantly viewed as the resident macrophages of the CNS. They are 
derived from a distinct monocytic lineage that migrate to the brain neonatally. During adulthood, 
microglia continuously scan their immediate microenvironment for signs of tissue damage and 
infection (Nimmerjahn et al., 2005). This state is often referred to as a “resting”, or quiescent 
state. However, upon activation by antigen or inflammatory mediators, microglia transform to an 
active state. Activated microglia express a wide range of immune-related genes, including pro-
inflammatory cytokines and major histocompatibility complex (MHC) class I/II, thereby capable 
of initiating and maintaining inflammation. Studies indicate increased microglial activation in 
patients as verified by imaging studies (Doorduin et al., 2009; van Berckel et al., 2008). 
In light of the increased support for immune disturbances in patients, and the relative lack of 
effect on the negative and cognitive symptoms by standard antipsychotic drugs, attention has 
turned to treatment options that target the immune system. Interestingly, the antimicrobial agent 
minocycline that inhibits microglial activation decrease negative symptoms in patients when 
added to antipsychotic drugs (Levkovitz et al., 2010; F. Liu et al., 2014). Similarly, 
cyclooxygenase (COX)-2 inhibitors have been shown to improve cognitive symptoms as an add-
on treatment (Müller et al., 2005). Treatment with COX-2 inhibitors in rats decreases brain levels 
of kynurenic acid (KYNA), which is detrimental to cognition (see 1.4; Animal models). It might, 
therefore, be speculated that the improved cognition are due to decreased levels of KYNA. 
1.2.2 The P2X7 receptor 
Purinergic signaling is a key immune regulatory mechanism. The P2 receptor family receives 
input from nucleotides and is further divided into P2Y and P2X receptors. P2Y receptors are G 
protein-coupled receptors (GPCRs) while P2X receptors, including P2X purinoceptor 7 (P2X7) 
are ion channels (Eltzschig et al., 2012; Jiang et al., 2013). P2X7 receptors are expressed by 
several cell types in the CNS, including astrocytes and microglia. The endogenous ligand of 
P2X7 is adenosine triphosphate (ATP), an abundant molecule that in addition to its energy 
carrying properties increases in tissues following events such as tissue damage and infection. In 
addition, ATP participates in glia-neuron signaling and modulates synaptic transmission (Fields 
and Burnstock, 2006). Activation of P2X7 induces channel opening, allowing K+ efflux from the 
cell. Although not fully clarified, the change in the [K+] gradient is believed to induce the opening 
 4 
of pannexin channels, which in turn via downstream signaling events, leads to the assembly of 
the inflammasome complex (Sperlágh and Illes, 2014). Caspase-1 is the critical component of 
the inflammasome in terms of IL-1β activation, as it cleaves pro-IL-1β into its active form 
(Martinon et al., 2007; Minkiewicz et al., 2013; Sanz and Di Virgilio, 2000). 
1.2.3 G-protein coupled receptor kinase 3 
G-protein coupled receptor kinase (GRK) 3, also known as ADRBK2, belongs to a ubiquitous 
family of kinases that primarily phosphorylates GPCRs and consequently inhibits their activity. 
Importantly, GRK3 phosphorylates P2X7 receptors (Feng et al., 2005), inhibiting further 
downstream signaling to caspase-1. Loss-of 
function of GRK3 may thus cause P2X7 
receptor overactivation, leading to excess 
IL-1β release (Figure 1). In line with the 
hypothesis of increased immune activation 
in psychiatric disorders, reduced expression 
of GRK3 has been found in the dorsolateral 
prefrontal cortex of patients with 
schizophrenia (Bychkov et al., 2011) and 
bipolar disorder (Rao et al., 2009; Shaltiel 
et al., 2006) 
1.3 KYNURENIC ACID AND SCHIZOPHRENIA 
Several lines of evidence point to dysregulation of the kynurenine pathway in schizophrenia. For 
instance, patients with schizophrenia display increased levels of KYNA in the CSF and post 
mortem brain (Erhardt et al., 2001a; Linderholm et al., 2012; Nilsson et al., 2005; Schwarcz et 
al., 2001). Further, studies show increased KYNA and decreased kynurenine monooxygenase 
(KMO) activity in post-mortem brain tissue from patients with schizophrenia (Sathyasaikumar et 
al., 2011; Wonodi et al., 2011). 
The first member of the kynurenine pathway described was KYNA, extracted from dog urine in 
1853 by Justus Von Liebig (Liebig, 1853). Over a decade later, KYNA was found to be present 
in the human brain (Moroni et al., 1988). Pharmacodynamically, KYNA acts as a non-
competitive antagonist at the glycine site of the N-Methyl-D-aspartic acid receptor (NMDAR, 
IC50 ≈ 8 – 15 µM). At higher concentrations it also blocks the glutamate recognition site of the 
NMDAR (IC50 ≈ 0.2 – 0.5 mM), and also the glutamate receptors of the α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate type (IC50 in the millimolar range). 
Further, KYNA competitively blocks the α7 subunit containing nicotinic acetylcholine receptor 
(α7nAChR, IC50 ≈ 7 µM, Hilmas et al., 2001). KYNA has also been shown to interact with the 
previous orphan receptor GPR35 (Wang et al., 2006), and the aryl hydrocarbon receptor 
Figure 1. GRK3 dependent phosphorylation of P2X7 
in astrocytes or microglia. 
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(DiNatale et al., 2010), although the physiological significance of these interactions have yet to 
be fully determined. 
1.3.1 The kynurenine pathway 
The majority of available tryptophan is broken down by the kynurenine pathway as opposed to 5-
hydroxytryptamine (5-HT, Serotonin) formation (Gál and Sherman, 1980).The initiation of 
tryptophan breakdown by the kynurenine pathway (Figure 2) is the oxidation of tryptophan into 
N-formyl-kynurenine by the rate-limiting enzymes of the kynurenine pathway, indoleamine 2,3-
dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO). N-formyl-kynurenine is then 
transformed to kynurenine, the central component of the pathway, by kynurenine formamidase. 
As kynurenine readily passes the blood-brain barrier (BBB), about 60% of the central pool of 
kynurenine is of peripheral origin (Gál and Sherman, 1980). From this point on, the pathway is 
spatially separated as kynurenine may be converted into KYNA by astrocytic kynurenine 
aminotransferases (KATs) I/II/III/IV, or into 3-hydroxykynurenine (3-HK) by microglial KMO. 
3-HK is then further metabolized into quinolinic acid (QUIN), which as opposed to KYNA is an 
agonist at the NMDAR with excitotoxic and seizurogenic properties (Lapin, 1978; Stone and 
Perkins, 1981). In fact, local QUIN administration into the brain has even been shown to induce 
lesions (Schwarcz et al., 1983). 
  
Figure 2. The kynurenine pathway of tryptophan breakdown. 
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1.3.2 Regulation of the kynurenine pathway 
The immune system exerts a strong influence on the kynurenine pathway. Upon immune 
activation, the release of pro-inflammatory cytokines such as IL-1β, IL-6, and interferon (IFN)-γ 
causes activation of the kynurenine pathway primarily through their action on IDO/TDO, see 
Campbell et al., 2014. Activation of the kynurenine pathway decreases available tryptophan, and 
it has been speculated that this might serve as a crude antibacterial mechanism, as tryptophan is 
essential to growing microbes (Zelante et al., 2009). The limiting factor in KYNA synthesis is 
the availability of kynurenine. The administration of kynurenine (Swartz et al., 1990) or KMO 
inhibitors (Moroni et al., 2005) therefore consistently increase KYNA in the CNS. Additionally, 
administration of probenecid, which blocks CNS KYNA efflux by the human organic anion 
transporters (hOATs), also reliably increases brain levels of KYNA (Uwai et al., 2012). 
1.4 ANIMAL MODELS OF SCHIZOPHRENIA 
Animal models of psychiatric disorders are valuable tools in research as they enable the 
controlled investigation of functional effects of suggested pathophysiological mechanisms. As 
psychiatric disorders display a plethora of symptoms, only particular traits are usually 
successfully modeled. Further, these traits may not be exclusive to a single disorder. For instance, 
anhedonia is a symptom usually present in both depression and schizophrenia that renders the 
affected individual unable to experience pleasure. This may be modeled in animals by measuring 
the absence of the hedonistic drive of drinking sweetened water. Animal models of schizophrenia 
may be broadly classified as developmental, genetic, lesional and pharmacological. These 
categories are however not mutually exclusive.  
Various types of behavioral assessments are usually performed in validating phenotypes, one 
such is prepulse inhibition (PPI) of the acoustic startle reflex. Here, the startle response to a short 
intense auditory stimulus (pulse) is measured with and without a preceding non-startling auditory 
short stimulus (prepulse). Failure by the prepulse to inhibit the startle response reflects deficits in 
sensorimotor gating, a common finding among patients with schizophrenia (Braff et al., 1978; 
Swerdlow et al., 2008). Such gating deficits have been suggested to reflect problems with 
filtering out irrelevant auditory stimuli, and intrusive thoughts (McGhie and Chapman, 1961). 
Moreover, PPI deficits can be induced in animals by various means, e.g. psychotomimetic drugs 
(Geyer et al., 2001), or targeted gene deletions (Powell et al., 2009), and rescued by 
administration of atypical antipsychotic drugs (Fijał et al., 2014; Li et al., 2011). 
Increased spontaneous and drug-induced hyperlocomotion may reflect abnormalities in 
dopaminergic transmission and are commonly tested in rodents. Further, there is an interaction 
between KYNA and the dopamine system, as elevation of KYNA potentiates amphetamine-
induced dopamine release (Olsson et al., 2009), and increases the firing activity of midbrain 
dopaminergic neurons (Erhardt et al., 2001b; Linderholm et al., 2007). 
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1.4.1 Developmental, genetic, and lesion models 
Developmental animal models entail insults to central developmental processes for example 
using NMDAR antagonists during the prenatal, perinatal or postnatal period. These insults may 
interfere with neuronal guiding (Reiprich, 2004), leading to behavioral disturbances in adulthood 
(Lim et al., 2012; Muraki and Tanigaki, 2015). In analogy with this, neonatal kynurenine 
treatment and influenza virus infection, both cause transient elevation of KYNA and induce 
behavioral aberrations in adult mice (X. C. Liu et al., 2014). 
Genetic models commonly involve the creation of knock-out (KO) mice by deletion of the gene 
of interest in mice, thus enabling the study of the phenotypic contribution of a single gene. 
Schizophrenia-like phenotypes have successfully been created by the deletion of suggested risk 
genes for schizophrenia. For instance, mice with deletion of “disrupted in schizophrenia-1” 
(DISC1), a gene associated with schizophrenia, display deficits in several behavioral parameters 
(Lipina and Roder, 2014). Deletions of genes related to immune function have also been reported 
to cause functional disturbances. In one study, virus infection caused deficits in sensorimotor 
gating in KO mice lacking the “transporter associated with antigen processing 1” (TAP1) gene, 
but not in wild-type mice (Asp et al., 2010). TAP1 KO mice lack functional CD8+ T-cells, 
resulting in increased activity of the innate immune (Asp et al., 2009). As described previously 
(see 1.3.1; The kynurenine pathway), KAT II converts kynurenine into KYNA. Notably, 
inactivation of KAT II by deletion (KO mice) or pharmacological blockade in rats and nonhuman 
primates improves cognitive function (Kozak et al., 2014; Potter et al., 2010), whereas there is a 
cognitive disrupting effect by increased KYNA (Alexander et al., 2012). 
Lesional models may entail permanent inactivation of brain areas with neurotoxic substances 
such as 6-hydroxydopamine, see Lipska and Weinberger, 2002. This model has however been 
criticized for it lack of construct validity. Interestingly, a transient lesion model has been 
developed where animals develop a similar phenotype as in the permanent model. Here, transient 
inactivation of the ventral hippocampus by postnatal tetrodotoxin administration causes cognitive 
deficits which are reversed by treatment with an α7nAChR agonist (Brooks et al., 2012). 
1.4.2 Immune models 
Induction of the immune system in humans and rodents induces a coordinated repertoire of 
behaviors termed “sickness behavior”. It has been suggested that this is a behavioral adaption 
induced by the immune system during infection to increase chances of survival, see Hart, 1988. 
In rodents, sickness behavior can reliably be induced by lipopolysaccharide (LPS), a component 
of the outer membrane of gram-negative bacteria (Dunn and Swiergiel, 2005). LPS is recognized 
by toll-like receptor (TLR) 4, which is present primarily on microglia and astrocytes in the CNS 
(Dong and Benveniste, 2001; Falsig et al., 2008). Activation of TLR4 induces a down-stream 
cascade that enables nuclear factor kappa B (NFκB) mediated transcription of pro-IL-1β and pro-
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IL-18 (Rhee and Hwang, 2000). This induces in addition to social withdrawal, decreased 
appetite, and fatigue, also symptoms congruent with certain aspects of the human state of 
schizophrenia and depression, such as anhedonia (Salazar et al., 2012; Walker et al., 2013) and 
cognitive deficits (Czerniawski et al., 2015; Haba et al., 2012; Ming et al., 2015). The 
behavioral aberrations in LPS treated rodents are likely mediated by activation of the kynurenine 
pathway as IDO inhibition ameliorates depressive-like symptoms, but not sickness per se 
(O'Connor et al., 2009). 
1.5 THE DOPAMINE AND GLUTAMATE HYPOTHESIS OF SCHIZOPHRENIA 
The impact of the dopamine system on the development and maintenance of psychosis is based 
on observations that enhancers of dopaminergic transmission such as amphetamine, exacerbate 
psychotic symptoms, while antagonists, such as antipsychotic drugs, ameliorate them (Carlsson 
et al., 2001; Sanfilipo et al., 1996; Snyder, 1973). Corroborating evidence has been provided in 
contemporary studies where the dopaminergic hyperresponsiveness following amphetamine is 
demonstrated in patients (Abi-Dargham et al., 1998; Abi-Dargham and Laruelle, 2005; Abi-
Dargham et al., 2000; Breier et al., 1997b; Laruelle et al., 1996). These findings form the basis 
of the dopamine hypothesis of schizophrenia. This hypothesis has however been revised as it 
poorly accounts for the negative and cognitive symptoms. The modified dopamine hypothesis, 
thus suggests that decreased dopaminergic transmission in prefrontal brain areas coexist with a 
midbrain hyperdopaminergic state (Davis et al., 1991) is now generally accepted. 
Aberrations in glutamatergic transmission have also been implicated in the pathophysiology of 
schizophrenia as low CSF glutamate levels in patients have been reported (Kim et al., 1980). In 
addition, NMDAR antagonists (e.g. ketamine, MK-801, and phencyclidine) aggravate psychotic 
symptoms in patients with schizophrenia (Lahti et al., 2001), and have been shown to induce 
psychotic symptoms from all spectra (Krystal et al., 2005) in healthy individuals (Allen and 
Young, 1978; Breier et al., 1997a). Interestingly, studies show that NMDAR antagonist-induced 
PPI deficits respond poorly to classical antipsychotics (Bakshi et al., 1994), while treatment with 
the atypical antipsychotic clozapine treatment reverses such PPI deficits and protects against 
ketamine induced psychosis (Malhotra et al., 1997). 
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2 AIMS 
 
• To study the influence of elevated brain KYNA on dopaminergic neurotransmission by 
studying the effect of kynurenine administration on amphetamine-induced 
hyperlocomotion in mice. 
 
• To measure CSF cytokines in patients with chronic schizophrenia and correlate to 
previously measured kynurenines from the same patients. 
 
• To investigate the effects of IL-6 administration on KYNA production in human fetal 
astrocytes. 
 
• To investigate biochemical aberrations and behavior in Grk3 mutant mice. 
 
• To study the importance of GRK3 on CSF KYNA levels and psychosis in patients with 
bipolar disorder. 
 
• To investigate the effect of dual versus single administration of LPS with respect to 
brain and serum kynurenines. 
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3 MATERIALS AND METHODS 
The following sections are brief descriptions of the materials and methods used. For details see 
the corresponding section in respective paper. 
3.1 DRUGS AND CHEMICALS (PAPERS I – IV) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See Table 1 for manufacturer details. For paper I, kynurenine was dissolved in sterile dH2O and 
pH was thereafter adjusted to ≈ 8.5 with NaOH. D-Amphetamine (paper I, III) and probenecid 
(paper III) were dissolved in sterile dH2O. LPS (Escherichia coli 0111:B4) in paper IV was 
dissolved in sterile saline. IL-1β (paper III) was dissolved in sterile dH2O to a concentration of 
0.1 mg/ml and further diluted with phosphate buffered saline (PBS). 
Compound Compound 
13C315N1-QUIN6 Lipopolysaccharide (LPS)1 
5-Hydroxytryptamine (5-HT)1 Methanol1 
Acetic acid1 NaCl1 
Acetonitrile1 NaOH1 
Acrylic dental cement (Dentalon®)3 Octanesulfonic Acid1 
Anti P2X7 Receptor antibody (APR-004)4 Perchloric Acid (PCA)1 
Anti β-Actin antibody Paraformaldehyde (PFA)1 
Bupivacaine (Marcain®)2 Phosphatase Inhibitor Cocktail I (P2850)1  
D-Amphetamine1 Phosphatase Inhibitor Cocktail II (P5726)1 
D4-5-HT1 Phosphatase Inhibitor Cocktail III (P0044)1 
D4-Kynurenine (D4-KYN)7 Phosphate buffered saline (PBS)1 
D5-Tryptophan (D5-TRP)1 Probenecid1 
Ethylene glycol tetraacetic acid (EGTA)1 Protease Inhibitor Cocktail (P8340)1  
Ethylenediaminetetraacetic Acid (EDTA)1 Protease Inhibitor Cocktail (11836170001)8 
Formic Acid1 Sodium Acetate1 
GFAP antiserum1 Sodium Dodecyl Sulphate1 
Horseradhish Peroxidase Conjugated 
Secondary Antibodies (7076, 7074) 
Sodium Metabisulfite1 
Interferon (IFN)-γ1 Tris-HCl pH 7.51 
Interleukin (IL)-1β, mouse1 Triton X-1001 
Isoflurane (Furane®)2 Tryptophan (TRP)1 
Kynurenic acid (KYNA)1 Tween 201 
L-Kynurenine1 Zinc Acetate1 
Table 1. Drugs and chemicals. Suppliers: 1. Sigma-Aldrich, Stockholm, Sweden 2. Astra 
Zeneca, Södertälje, Sweden 3. Heraeus, Hanau, Germany 4. Alomone Labs, Jerusalem, Israel 
5. Cell signaling Technology, Danvers, MA, USA 6. Synfine Research Inc., Ontario, Canada 
7. Buchem B.V., Apeldoorn, The Netherlands 8. Roche Diagnostics Corporation, Indianapolis, 
IN, USA 
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The lysis buffer in paper III contained 150 mM NaCl, 20 mM Tris pH 7.5, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 1mM ethylene glycol tetraacetic acid (EGTA), 1 % 
triton X-100. The complete hypotonic buffer in paper III was prepared by adding 10 µl NaHCO3 
(1 M) to 9 990 µl dH2O, to which phosphatase inhibitor cocktail I (1:1 000), II (1:1 000), and 
protease inhibitor cocktail (P8340, 1:1 000) were added. Complete extraction buffer was 
composed of 0.50 % Triton X-100, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 % 
sodium dodecyl sulfate, protease inhibitor cocktail, phosphatase inhibitor cocktail I, II. Tris buffer 
for western blotting was composed of 50 mM Tris-HCl, 6 mM NaCl, and 0.1 % Tween 20. The 
anti P2X7 receptor and anti β-actin antibodies were diluted 1:10 000. 
For immunohistochemistry experiments in paper III, the following solutions were used: 4 % 
para-formaldehyde (PFA) containing 0.4 % picric acid in 0.16 M phosphate buffer (pH 6.9), TNT 
buffer (0.1 M Tris-HCl (pH 7.5), 0.15 M NaCl, 0.05 % Tween 20), TNB buffer (0.1 M Tris-HCl 
(pH 7.5), 0.15 M NaCl, 0.5 % blocking reagent). The anti-rabbit horseradish-peroxidase 
conjugated secondary antibody was diluted in TNB buffer for 30 min (1:200). The Biotinyl 
tyramide fluorescein conjugate was diluted 1:1 200 in amplification diluent. 
Artificial CSF (aCSF, paper III) contained 148 mM NaCl, 4 mM KCl, 0.8 mM MgCl2, 1.4 mM 
CaCl2 in dH2O. The mobile phase (papers I – IV) for detection of brain/serum KYNA and serum 
kynurenine was 50 mM sodium acetate in ultra-pure dH20 (adjusted to pH 6.2 with acetic acid) 
with 7 % acetonitrile. The mobile phase composition for electrochemical detection of brain tissue 
dopamine, 5-HT, 5-Hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3,4-
Dihydroxyphenylacetic acid (DOPAC) in paper IV was (concentrations used in paper III for 
microdialysate analysis are in parenthesis): 70 (55) mM sodium acetate, 1.5 (1.16) mM 
octanesulfonic acid, 0.01 mM EDTA, 20 (10) % Methanol, in dH2O. pH was adjusted to 4.1 with 
acetic acid. The perchloric acid (PCA) solution for tissue homogenization was composed of 70% 
PCA diluted to 0.4 M in dH20, containing 0.1 % sodium metabisulfite and 0.05 % EDTA.  
3.2 ASTROCYTE CULTURES (PAPER II) 
Human embryonic primary cortical astrocytes (ScienCellTM Research Laboratories, Carlsbad, CA 
USA) in passage four were starved for 24 h (0.02 % fetal bovine serum, 0.01 % growth 
supplement mix). Next, 10 ng/ml IL-6 was applied and supernatants were collected after 24, 48, 
and 72 h, and immediately put on dry ice and stored at -80 °C until analysis. Cells were cultured 
according to manufacturers protocols and experiments were performed in triplicates, repeated 
twice. 
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3.3 P2X7 INTERNALIZATION (PAPER III) 
3.3.1 Separation of membrane fractions 
Mice brain tissue was homogenized in complete hypotonic buffer and then centrifuged for 10 min 
4 °C (1 200 × g). The supernatant was centrifuged (21 600 × g, 4 °C, 30 min), and the resulting 
internal membrane-containing pellet (P2) was resuspended in complete extraction buffer. The 
supernatant was centrifuged at 150 000 × g for 2 h at 4 °C and the plasma membrane-containing 
pellet (P3) was dissolved in complete extraction buffer. P3 was then washed with complete 
hypotonic buffer and centrifuged for 2 h at 150 000 × g (4 °C). This pellet was resuspended in 
complete extraction buffer. A PierceTM BCA protein assay kit (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) was used for protein content determination according to manufacturers 
recommendation. 
3.3.2 Western blot 
P2 and P3 containing fractions were separated on a NuPAGE 4 – 12 % Bis-Tris gel (Invitrogen, 
Carlsbad, CA, USA) before being transferred to nitrocellulose membranes (Invitrogen). The 
membranes were then blocked with reconstituted dried milk (5 % in Tris buffer) for 1 h at room 
temperature. Next, membranes were incubated with a primary antibody against P2X7 overnight 
at 4 °C. Following three washes (5 min each), membranes were incubated with horseradish 
peroxidase conjugated secondary antibodies at room temperature for 1 h. Chemiluminescent 
detection reagents (SupersignalTM West Pico, West Femto, Thermo Fisher Scientific Inc.) were 
used to visualize specific bands. An anti β-actin antibody was used as protein loading control to 
which the P2X7 signals were normalized. The Quantity One software (Bio-Rad Laboratories, 
Hercules, CA, USA) was used for signal intensity measurements. 
3.4 IMMUNOHISTOCHEMISTRY (PAPER III) 
Mice were anesthetized with pentobarbital (50 mg/kg) and perfused via the ascending aorta with 
37 °C Tyrode's solution (Ca2+ free) followed by 37 °C, 4 % PFA. Next, mice were perfused with 
4 °C, 4 % PFA and decapitated. Brain were harvested and immersed in ice-cold PFA for 90 min 
and rinsed overnight in phosphate-buffered 10 % sucrose, set to pH 7.4. Before being thaw-
mounted (Superfrost® slides, WVR International, Radnor, PA, USA) brains were CO2 frozen and 
cut in 14 µm sections in a cryostat (Microm, Heidelberg, Germany). Sections spanning around he 
bregma (0.98-(-2.30)) were included in the analysis and were pretreated with 0.03 % H2O2 and 
incubated with glial fibrillary acidic protein (GFAP) antiserum overnight 4 °C. Brain sections 
were then processed according to the TSA-plus Fluorescein System (PerkinElmer, Waltham, 
MA, USA). In short, sections were washed in TNT buffer and then incubated in TNB buffer (30 
min each at room temperature). Next, sections were incubated with an anti-rabbit horseradish-
peroxidase conjugated secondary antibody in TNB buffer for 10 min at room temperature. 
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Sections were analyzed with a Nikon Eclipse E600 Fluorescence microscope equipped with 10X 
objective. The GFAP labeling was quantified using the Image J Software (National Institutes of 
Health). In brief, the area of interest was encircled on micrographs and the sum of labeling with 
intensity above a set threshold was calculated by the program (raw integrated density). 
3.5 ANIMALS (PAPERS I, III, IV) 
Sixty male adult C57BL/6 mice (Charles River Laboratories, Inc., Sulzfeld, Germany) were used 
in paper I. In paper III, 36 male Grk3-/- mice (B6.129-Adrbk2tm1Rjl/J) on a C57BL/6 background 
were used (The Jackson Laboratory, Bar Harbor, ME, USA, detailed in (Peppel et al., 1997)). 
Thirty-four Grk3+/+ littermates were used as controls. In-house bred male adult C57BL6 mice 
were used for KYNA analysis post intracerebroventricular (ICV) IL-1β injection (n = 35), as well 
as in paper IV (n = 136). Environmental conditions were checked daily and maintained under 
constant temperature (25°C) and humidity (40–60 %) in a room with 12 h light/dark cycle (lights 
on at 06.00 hours). Food and water was provided ad libitum. Experiments were approved by and 
performed in accordance with the guidelines of the Ethical Committee of Northern Stockholm, 
Sweden. Animals tested for PPI deficits post ICV IL-1β in paper III were male adult C57BL6 
mice. These experiments were performed and animals were housed at the University of 
California San Diego (UCSD). 
3.6 TISSUE COLLECTION AND PREPARATION (PAPERS I – IV) 
Animals were sacrificed by decapitation following isoflurane anesthesia (≈ 4 %). Blood from 
animals in paper IV was acquired by either cardiac puncture or collected from the trunk after 
decapitation. Blood samples were collected in eppendorf tubes and allowed to coagulate over 
night at 4 °C. The following day, serum was collected and centrifuged for 15 min at 1500 × g 
before being transferred to new eppendorf tubes and stored at -80 °C. In paper I, III, and IV, 
brains were swiftly removed from decapitated animals, and hippocampi (paper III) were 
collected. Brain tissue were immediately frozen on dry ice, collected in eppendorf tubes and 
stored at -80 °C.  
Prior to analysis, tissue and astrocyte media (paper II) samples were (brain tissue: three to 
sevenfold (w/w), serum and astrocyte media: onefold (v/v)) diluted in 0.4 M PCA solution. Brain 
tissue was then homogenized by a disperser (Ultra-Turrax®, IKA, Stauffen, Germany). Brain 
homogenates, serum, and astrocyte media mixtures were centrifuged for 5 min at 20 000 × g and 
supernatants were transferred to new eppendorf tubes. Supernatants were then further 10 % 
diluted by the addition of pure PCA, vortexed, and centrifuged again at 20 000 × g for 5 min 
before being transferred to new tubes. Hippocampal tissue in paper III for IL-1β detection was 
homogenized using a Bullet Blender® (2 × 3 min, 4 °C, Next Advance inc., Averill park, NY, 
USA) in ice-cold lysis buffer with added protease inhibitor (no. 11836170001) and phosphatase 
inhibitor II and III. The homogenates were then centrifuged at 16 000 × g and 50 µl supernatant 
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was used for analysis. For paper IV, mice hemi brains were weighed and sonicated in 600 µl 
PBS buffer. After ultracentrifugation (30 000 × g, 4 °C), internal standards in 5 % formic acid 
were added to supernatants (50 µl), which were filtered (3 000 × g, 60 min) using 10kDa 
Ultracel®-10 filter plates (Millipore, Darmstadt, Germany). Serum samples (paper IV) and 
astrocyte media (paper II) were solid-phase extracted (Oasis® MAX, Waters Corporation). 
Before washing and elution (60% acetonitrile, 38 % methanol and 2 % formic acid) of analytes, 
cartridges were equilibrated and internal standards were added (in 5 % ammonium hydroxide). 
The organic phase was evaporated with nitrogen and redissolved in 2.5 % (serum samples), or 0.1 
% (astrocyte media) formic acid. 
3.7 HUMAN SUBJECTS (PAPERS II, III) 
Briefly, in paper II, olanzapine-treated patients with schizophrenia or schizoaffective disorder 
were recruited during 2005 – 2007. Patients were somatically healthy at recruitment. Smoking 
was allowed, as well as co-medication with zopiclone and lithium. Symptoms were rated with the 
Brief Psychiatric Rating Scale (BPRS) and Global Assessment of Functioning (GAF) scale. Full 
study details have been previously published (Skogh et al., 2011) as well as methods for 
olanzapine analysis (Josefsson et al., 2010). Controls were collected in 2005 – 2008 among 
medical staff, medical students, and their relatives. These were free from somatic and psychiatric 
conditions as verified by a medical and psychiatric evaluation. Further, none of the healthy 
volunteers had a family history of serious psychiatric disorder and were medication-free for at 
least one month. 
In Paper III, data from euthymic bipolar disorder outpatients were collected from the Northern 
Stockholm psychiatric clinic. Healthy controls were randomly selected by Statistics Sweden. 
Cohorts underwent the same clinical evaluation. Study details have previously been published, 
including diagnostics (Jakobsson et al., 2013; Olsson et al., 2012), CSF analyses (Olsson et al., 
2012), and genotyping (Bergen et al., 2012). eQTL data from the HapMap2 sample was accessed 
through SNPexp v1.2. (http://app3.titan.uio.no/biotools/tool.php?app=snpexp). The analysis was 
based on an additive model. Studies were carried out according to the declaration of Helsinki. All 
patients and healthy volunteers received verbal and written information about the study and 
provided written consent. 
3.8 ANIMAL SURGERY 
3.8.1 Microdialysis surgery (paper III) 
Mice were put in a plastic induction chamber and anesthetized with 4% isoflurane delivered by 
an Univentor 400 anesthesia unit (Univentor, Zejtun, Malta). When both righting reflex and 
response to toe pinch were absent, mice were attached to a stereotactic instrument (David Kopf 
Instruments, Tujunga, CA, USA). Isoflurane was continuously delivered by a nose cone and mice 
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body temperature were maintained at 37 °C by a heat pad (Homeothermic Blanket Control Unit 
50-7053-F, Harvard Apparatus, Holliston, MA, USA). After an ocular lubricant had been applied, 
the head was shaved and swabbed with ethanol. A small incision (< 1 cm) was then made along 
the midline of the head and wound edges were retracted. The skull was then swabbed clean, and 
bupivacaine (5 mg/ml) was applied. A thin layer of quick-setting cyanoacrylate glue (BT AB, 
Stockholm Sweden) was applied to reinforce the skull and allow the cement to attach. The 
stereotactic instrument was then positioned according to the coordinates (hippocampus 
anterior/posterior (AP): -2.9 mm, medial/lateral (ML): -3.2 mm, dorsal/ventral (DV): -1.5 mm; 
striatum AP: +0.5 mm, ML: -2 mm, DV: -1.5 mm) and a small hole was drilled. A guide cannula 
(AT4.7.IC, AgnTho's AB, Stockholm, Sweden) containing a dummy probe was then inserted. 
The guide cannula was fixated with acrylic dental cement and allowed to settle for ≈ 5 – 10 min. 
Mice were given 0.5 ml saline subcutaneous (s.c.) before the wound was sutured, and animals 
were allowed to recover single-housed for 24 h. Stereotactic coordinates were according to the 
mouse brain atlas by Paxinos (Paxinos and Franklin, 2008). 
3.8.2 Intracerebroventricular IL-1β injection (paper III) 
3.8.2.1 Biochemical measurements 
The procedure was according to microdialysis surgery up to the point of cannula insertion with 
the exception that no glue was applied. Here, a small glass capillary was instead positioned and 
inserted into the ventricle (AP: -0.34 mm, ML: -1 mm, DV: -2 mm). Four µl of IL-1β (0.125, 
0.25, 1.25, or 2.5 ng/µl) was then infused over 8 min, and the capillary was allowed to stay for 5 
additional min to prevent backflow of liquid. The wound was then closed with metal clips and 
mice were given 0.5 ml saline s.c.. Mice were sacrificed 6 h post-infusion and tissues were 
collected. 
3.8.2.2 PPI experiments 
These experiments were conducted at The University of California, San Diego (UCSD). Surgery 
was performed as described previously (Vinkers et al., 2007). Briefly, a stainless steel guide 
cannula was implanted above the lateral ventricle. Mice recovered for 5 days prior to behavioral 
testing. Immediately prior to PPI experiments, IL-1β or vehicle were infused through an injector 
in a volume of 0.5 µl. At the end of the study, cannula placement was checked via dye infusion. 
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3.9 PPI (PAPER III) 
3.9.1 Grk3 -/- mice 
 PPI was performed in two SR-LAB™ sound-attenuated cabinets measuring 35×33×46 cm (SD 
instruments, San Diego, CA, USA). An enclosed loudspeaker provided the acoustic stimuli 
(white noise) as background (65 dB) and tone bursts. Here, mice were placed in a plexiglass 
enclosure (3.7 cm in diameter) connected to a piezoelectric accelerometer (SD instruments). The 
accelerometer was connected to a standard personal computer running the startle analysis 
software (SD instruments). The same person performing the experiments handled all mice for up 
to a week prior to the PPI session. PPI experiments started with a baseline run consisting of four 
P120 trials opening and ending the session. In between there were six evenly distributed 
PP12P120 trials with two P120s between each. The experimental session entailed a 5 min 
habituation period to background noise (continuous throughout session), followed by five P120s. 
This was immediately followed by a variable stimulus intensity block containing five trial types: 
P120, P110, P100, P90, and P80, each 
presented four times. A variable prepulse 
intensity block (Table 2) consisting of 12 
P120 trials, and ten trials each of PP4P120, 
PP8P120, and PP16P120, then followed, 
see Table 2. Next, a variable interstimulus 
interval block (Table 2) was presented to 
the mice. Here, four each of the trials: 
ISI500, ISI200, ISI100, ISI50, and ISI25 
were presented to the mice. Eight single 
P120s were scattered within the block. 
Throughout the session, NS trials were 
presented in between each trial. All trial 
types within each block were presented in a 
pseudo-randomized order with an average 
inter-trial interval of 7.5 s (not including 
the trials without acoustic stimulus). The 
session ended with five P120s for startle 
habituation assessment. The mean of the 
first 65 accelerometer readings (each 1 ms 
long) was defined as mean startle 
magnitude. Percent PPI was calculated 
using the formula: %  𝑃𝑃𝐼 = ((𝐴 −𝐵)/𝐴)×100, where A = Mean startle magnitude of P120 trials within blocks, and B = Mean 
startle magnitude of the prepulse+pulse trials within the same block. 
Table 2. 
Trial 
name 
Intensity 
(dB) 
Length 
(ms) 
Interval 
(ms) 
A. Single pulse trials 
P120 120 40 - 
P110 110 40 - 
P100 100 40 - 
P90 90 40 - 
P80 80 40 - 
B. Prepulse + pulse trials 
PP16P120 16+120 20+40 80 
PP12P120 12+120 20+40 80 
PP8P120 8+120 20+40 80 
PP4P120 4+120 20+40 80 
C. Interstimulus interval trials 
ISI500 8+120 20+40 480 
ISI200 8+120 20+40 180 
ISI100 8+120 20+40 80 
ISI50 8+120 20+40 30 
ISI25 8+120 20+40 5 
NS - 40 - 
dB are decibels over background (65dB). Interval is 
the time between end of prepulse and start of pulse. 
NS = No stimulus 
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3.9.2 IL-1β infused mice 
These sessions were run at UCSD and have been described previously (Gresack and Risbrough, 
2011). Briefly, startle testing began immediately after IL-1β infusion and continued hourly for six 
hours. The PPI session lasted 20 min and mice were returned to their home cage in between 
sessions. 
3.10 LOCOMOTOR ACTIVITY (PAPER I) 
 Locomotor activity (LA) performance was tested in four square plexiglass containers measuring 
50×50×21.6 cm (ADITECH, Fjärås, Sweden). The containers were placed inside unlit boxes that 
were equipped with two layers of photocells 
(16 per wall and level, 3.1 cm apart), creating 
an infrared grid allowing measurement of the 
factors listed in Table 3. Beam breaks were 
registered and counted by a standard personal 
computer. The same person performed all tests 
between 6 a.m. and 6 p.m. Mice were either 
treated with kynurenine i.p. acutely (10 mg/kg 
immediately prior to session (n = 20) or 
subchronically (100 mg/kg, twice daily for six 
days, n = 9). Control animals received saline 
i.p. (acute, n = 18; subchronically, n = 13). 
The experiment consisted of three 60 min LA 
sessions 24 h apart. The third session was considered the test session for spontaneous LA. 
Immediately after the third session mice received a 5 mg/kg injection of amphetamine i.p. (acute 
kynurenine/saline, n = 13/12; subchronic kynurenine/saline, n = 5/7) or saline i.p. (acute 
kynurenine/saline, n =7/6; subchronic kynurenine/saline, n = 4/5) and amphetamine-induced LA 
was measured for an additional 90 min. Mice were sacrificed immediately after the last session. 
3.11 MICRODIALYSIS (PAPER III) 
All microdialysis experiments were performed in freely moving animals in their home cage. 24 h 
post-surgery, mice were tethered to a liquid swivel and the dummy probe was replaced with an 
AT4.7.2.PES probe (shaft length: 7 mm, membrane length: 2 mm, molecular cut-off: 6 kDa, 
AgnTho’s AB). The probe was continuously perfused with aCSF at 1 µl/min, delivered by a 
Univentor 864 (Univentor Ltd). The dialysate was collected in polypropylene tubes, which was 
either analyzed or frozen every 30 min. Experiments started by acquiring three stable baseline 
readings for determination of basal extracellular KYNA or dopamine levels. Mice were then 
given i.p. probenecid (200 mg/kg) or amphetamine (2 mg/kg), and microdialysis sessions 
continued for up to six h. 
Table 3.  
Measure Definition 
Horizontal Activity Total count of beam 
breaks in the lower level 
Peripheral Activity Number of beam breaks 
along box walls 
Forward 
Locomotion 
New beam breaks in the 
lower horizontal plane 
Corner Time Accumulated time in 
seconds of two peripheral 
simultaneous beam breaks 
Rearing Activity Number of beam brakes in 
the upper level 
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3.12 LPS INJECTIONS (PAPER IV) 
Animals were divided into the following groups; i) saline+saline ii) LPS+saline iii) LPS+LPS iiii) 
saline+LPS*. LPS was administered i.p. (0.83 mg/kg per injection). There were 16 hours between 
the first and second injection. 
Animals were sacrificed 24, 48, 72, 
and 120 hours after the first injection 
(Figure 3). * Group to control for 
time between last LPS injection and 
time of sacrifice in group iii. In 
addition, a group of mice received a 
single 1.66 mg/kg LPS to account 
for total dose injected in group iii. 
3.13 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (PAPERS I – V) 
3.13.1 Fluorescent detection (papers I – IV) 
Brain homogenates and serum samples were run through an isocratic high-performance liquid 
chromatography (HPLC) system. 50 µl of sample or 30 µl dialysate was manually injected into a 
100 µl loop through a Rheodyne® 7725i valve (IDEX, Oak Harbor, WA, USA). The mobile 
phase was pumped through a 4 × 100 mm reversed-phase ReproSil 100 C18, 3 µm column (Dr. 
Maisch GmbH, Ammerbuch, Germany), at 0.5 ml/min. The eluate was then run through a 
Shimadzu SPD-10A UV-Vis detector (Shimadzu Corporation, Kyoto, Japan) set to 360 nM for 
quantification of kynurenine in serum samples. The mobile phase was thereafter mixed with a 0.5 
M zinc acetate buffer delivered at 10 ml/h by a Pharmacia P-500 (Pharmacia, Uppsala, Sweden). 
Brain and serum KYNA was quantified by a Jasco FP-2020 Plus fluorescence detector (excitation 
wavelength: 344 nm, emission wavelength: 398 nm, bandwidth: 18 nm. Jasco Ltd., Hachioji City, 
Japan). Signals from the detectors were transferred to a personal computer and analyzed by 
Azure® (Datalys, Grenoble, France). KYNA (30 nM down to 0.156 nM) and kynurenine (5 µM to 
0.156 µM) standards were run throughout the session to confirm linearity and for interpolation of 
unknown values. Retention times were; KYNA (7 min), and kynurenine (4 min). 
3.13.2 Electrochemical detection (papers III, IV) 
Twenty µl of brain homogenate samples were diluted and neutralized in 160 µl dH20 and 20 µl 1 
M NaOH. Twenty µl of neutralized homogenate or 30 µl dialysate were manually injected into an 
electrochemical HPLC system through a Rheodyne 7125 (IDEX) valve. The mobile phase was 
pumped at 0.7 ml/min by a Shimadzu LC-20AD (Shimadzu Corporation). Analytes were 
separated by a reversed phase Zorbax® 3.5 µm Eclipse XDB-C18, 4.6 x 150 mm column (Agilent 
Technologies, CA, USA). Electric currents were obtained from a Coulochem III potentiostat 
 
Figure 3. Treatment regime used in paper IV 
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(ESA Inc., Chelmsford, MA, USA) with a 500 mV applied potential that controlled a high-
sensitivity ESA 5011A analytical cell (ESA Inc.). Signals were transferred to a standard personal 
computer running Clarity® (DataApex, Prague, The Czech Republic). Samples were quantified 
against a standard mixture containing 10 nM each of dopamine, HVA, DOPAC, 5-HT, and 5-
HIAA. Retention times in minutes: dopamine (6), DOPAC (4), HVA (7), 5-HT (11.5), 5-HIAA 
(5.5). 
3.14 LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY (PAPERS II, IV) 
Brain sample filtrates (paper IV) were injected (7.5 µl) into an ACQUITY HPLC system 
(Waters Corporation, Milford, MA, USA) equipped with a SymmetryShieldTM RP18 2.1 × 100 
mm, 3.5 µm particle column (Waters Corporation). The mobile phase was run at 300 µl/min and 
was 2.1% formic acid in MilliQ water (A phase) and 95% acetonitrile, 0.1% formic acid (B 
phase) starting with 5% B in A for 2 min and followed by gradient elution, total run time of 10 
min. Retention times for QUIN, kynurenine, and tryptophan were 1.1, 1.6, and 3.5 minutes 
respectively. Extracted serum samples (paper IV) and astrocyte media (paper II) were injected 
in the same manner (7.5 µl) into an ACQUITY HPLC. Here, the system was equipped with an 
HSST3 2.1 × 100 mm, 1.8 µm particle column (Waters Corporation). The mobile phases used 
here were of the same composition as previously and were run at the same flow rate. The run was 
started with 2 % B phase in A for 2 min followed by gradient elution and total run time was 15 
min. Retention times were: QUIN (1.5 min), kynurenine (3.9 min), tryptophan (5.9 min), and 5-
HT (3.6 min). 
Detection was performed using a Xevo TQ-S triple quadrupole mass spectrometer (Waters 
Corporation) operating in positive ionization MS/MS configuration. The mass spectrometer was 
tuned for all analytes and the mass spectral transitions were set at m/z 168> 106; 209>146; 205 > 
118, 190>116 and 177 > 115 and for the internal standard 172> 110 (13C315N1-QUIN), 213>150 
(D4-kynurenine), 210 > 123 (D5-tryptophan), and 181>118 (D4-5-HT). Standards of each analyte 
were used to establish a linear calibration curve and plotted using the ratio of analyte peak area 
over internal standard peak area after integration by Masslynx 4.1 software (Waters Corporation). 
3.15 ELECTROCHEMILUMINESCENT DETECTION (PAPERS II, III) 
Analyses were performed as per manufacturers protocol on a Sector Imager 2400 (Meso Scale 
Diagnostics, Rockville, MA, USA). A customized Human Ultra-Sensitive 10-Plex Kit was 
employed in paper II and a Mouse ProInflammatory 7-Plex Tissue Culture Kit in paper III 
(both from Meso Scale Diagnostics). Lowest levels of detection were: 0.06 pg/ml (paper II), 
0.04 pg/ml (paper III) for IL-1β, and 0.26 pg/ml (IL-6, paper II). Samples were run in 
duplicates. 
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3.16 STATISTICS 
Analyses were performed using Prism® 6 (GraphPad Software) for Mac OS X, unless otherwise 
stated. Tests were two-tailed and p values < 0.05 were considered significant unless specifically 
stated otherwise. 
3.16.1 Paper I 
Spontaneous LA data were analyzed with the Mann-Whitney test or an unpaired t-test. 
Comparisons were done on area under the curve (AUC) data from time points between 35 – 60 
min post kynurenine or saline injections. Amphetamine-induced LA data were analyzed with 
two-way analysis of variance (ANOVA, pretreatment × challenge), on AUC between 0 – 90 min 
post amphetamine or saline challenge. Whole-brain KYNA comparisons were done with the 
Mann-Whitney test. Comparisons were done with Prism® 4 and presented as mean ± SEM. 
3.16.2 Paper II 
Comparisons of cytokines and kynurenines between patients and controls were performed using 
the Mann-Whitney test. Levels are expressed as median and interquartile range. Age-adjusted 
calculations were performed with SPSS statistics (IBM Corporation, Armonk, NY, USA) using 
logistic regressions with age as a covariate and groups as dependent variable. For associations 
between patient variables, Spearman's rank correlation analyses were performed with SPSS 
statistics (IBM corporation). Levels of KYNA in astrocyte media were compared to controls 
within each time point using one-way ANOVAs with Bonferroni corrections. Data are here mean 
± SEM. 
3.16.3 Paper III 
Differences in % PPI were evaluated with repeated measures two-way ANOVAs using prepulse 
intensity or interstimulus interval as the repeated measure, and genotype or treatment as between 
group factors. To account for multiple testing Tukey's post-hoc test was used. In the microdialysis 
experiments, the mean of the three first samples was considered baseline, all other sample levels 
were expressed as the percentage of deviation from this mean. Within groups (pre vs. post-drug) 
comparisons were done using repeated measures one-way ANOVA. Between group comparisons 
(Grk3+/+ vs. Grk3-/-) was done with repeated measures two-way ANOVA (genotype × time). 
Post-hoc Bonferroni corrections were used in both cases. The Mann-Whitney nonparametric test 
was used to compare P2X7 levels in membrane fractions, hippocampal IL-1β levels, levels of 
basal kynurenines, and the average startle magnitude in PPI experiments. The parametric t-test 
was used for comparisons between groups in the immunohistochemistry experiments.  
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3.16.4 Paper IV 
Comparisons of brain and serum kynurenines, 5-HT, dopamine, and their metabolites were 
performed using the Kruskal-Wallis non-parametric test. Dunn's Post-hoc test was used to correct 
for multiple comparisons. Values are here mean ± SEM. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
Patients with schizophrenia display increased central levels of KYNA as well as amphetamine-
induced dopamine release as evidenced by increased [11C] raclopride receptor displacement (see 
1.5; The dopamine and glutamate hypothesis). In this paper, we aimed to further explore this 
relationship by studying the effect of elevated KYNA on spontaneous and amphetamine-induced 
locomotion in mice. 
4.1.1 Acute kynurenine administration 
Mice treated acutely with i.p. kynurenine (10 mg/kg, n = 20) 60 min prior to open-field trials 
displayed increased anxiety in comparison to vehicle (n = 19) treated mice. This was shown by 
increased amount of time spent in corners (Mann-Whitney, p = 0.02, Figure 4A, and increased 
percentage of peripheral activity (t-test, p = 0.03, Figure 4B). Other parameters tested tended to 
decrease by acute kynurenine treatment but did not reach statistical significance (horizontal 
activity, p = 0.10, forward locomotion, p = 0.08, rearing activity, p = 0.09). Acute kynurenine did 
not augment amphetamine-induced LA (data not shown). 
 
4.1.2 Subchronic kynurenine administration 
In contrast to acute treatment with kynurenine, mice treated subchronically with kynurenine (100 
mg/kg twice daily, i.p.) did not display increased anxiety in open-field trials. Further, subchronic 
treatment with kynurenine potentiated an amphetamine (5 mg/kg) challenge. Here, interactions 
(pretreatment × challenge) were significant for the measures: horizontal activity (p = 0.01, Figure 
5A), forward locomotion (p = 0.005, Figure 5B), and rearing activity (p = 0.01, Figure 5C).  
 
Figure 4. Corner time (A) and % peripheral activity (B) in mice treated acutely with kynurenine (Kyn, 
10 mg/kg, i.p.) versus controls given saline (Sal). Area under the curve 35 – 60 min post-injection was 
used for statistics. * = p < 0.05, (A) Mann-Whitney, (B) t-test. 
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Post hoc tests were significant between pretreatment (kynurenine versus saline) groups in all 
three measures (Bonferroni, p < 0.01). These data are in line with previous experiments, where 
rats treated with kynurenine subchronically, but not acute, displayed augmented amphetamine-
evoked dopamine release (Olsson et al., 2009). 
 
 
Figure 5. Differences in (A) horizontal activity, (B) forward locomotion, and (C) rearing activity in 
mice subchronically treated with kynurenine (Kyn, 2 × 100 mg/day). Amphetamine was injected at 
time = 0. Saline (Sal) was used as control. Bars represent area under the curve between time 0 – 90 min 
(mean ± SEM). ** = p < 0.01, +++ = p < 0.001 (versus respective saline challenge). Two-way ANOVA 
(pretreatment × challenge) with Bonferroni corrections. 
 24 
4.2 PAPER II 
In this paper, a well-characterized cohort of patients was analyzed with respect to CSF cytokines 
and compared to healthy controls. Associations between IL-6 and previously measured 
kynurenines were also explored, as well as the effects of IL-6 application on the synthesis of 
kynurenine and KYNA in cultured human fetal astrocytes. 
4.2.1 CSF levels of IL-6 and IL-8 in patients 
CSF IL-6 was reliably detected in 21 patients with schizophrenia and in all healthy controls (n = 
37). IL-8 was detected in 22 patients and in 36 controls. Comparisons between groups revealed 
significantly higher IL-6 levels in patients (2.68 pg/ml, IQR 1.80 – 3.99, versus 1.5 pg/ml IQR 
1.01 – 2.25, p < 0.001, Figure 6A). After stratifying by gender, IL-6 levels were still higher in 
both male (2.68 pg/ml, IQR 1.67 – 3.88, n = 15), and female patients (3.25 pg/ml, IQR 1.92 – 
5.83, n = 6) compared to respective controls (males: 1.12 pg/ml, IQR 0.85 – 1.68, n = 23, p = 
0.006, females: 1.76 pg/ml IQR 1.41 – 2.59, n = 14, p = 0.026). IL-8 levels did not differ between 
groups (Figure 6B). Correlation analyses were then performed to rule out the possibility of age 
confounding. Here, neither IL-6 nor IL-8 correlated with age and comparisons between groups 
were still significant after adjusting for age. 
 
 
 
Figure 6. Cerebrospinal fluid (CSF) levels of interleukin (IL)-6 (A) and IL-8 (B) in patients with 
schizophrenia (IL-6, n = 21; IL-8, n = 22) compared to healthy controls (IL-6, n = 37; IL-8, n = 36). 
Horizontal bars are medians. *** = p < 0.001 (Mann-Whitney). 
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4.2.2 Analyses of tryptophan metabolites 
In accordance with previous studies (see introduction for overview), CSF levels of KYNA (1.87 
nM, IQR 1.63 – 2.29) and kynurenine (57.88 nM, IQR 48.0 – 71.3) were higher in patients (n = 
23) as revealed by age-adjusted comparisons to controls (n = 37, KYNA: 1.50 nM, IQR 1.14 – 
1.92, p = 0.006; kynurenine: 32.22 nM, IQR 26.2 – 49.0, p = 0.04). Tryptophan levels did not 
differ between groups, however, there was an increased activity in the kynurenine pathway in 
patients, indicated by significantly decreased tryptophan:kynurenine, and tryptophan:KYNA 
ratios (age-adjusted, data not shown). Further correlational analyses also showed a significant 
association between IL-6 levels and the tryptophan:KYNA ratio in patients only (r = -0.49, p = 
0.024). 
 
 
 
4.2.3 IL-6 induced production of KYNA in astrocytes 
To further investigate the putative connection between IL-6 and activation of the kynurenine 
pathway, astrocytes were treated with IL-6 and cell media concentrations of KYNA and 
kynurenine were analyzed for up to 72 h post-administration. Analyses showed increased 
production of KYNA in astrocytes at 48 h (n = 6, IL-6: 1.55 ± 0.097 nM; Control: 1.29 ± 0.054 
nM) and at 72 h (n = 5, IL-6 1.83 ± 0.070 nM; Control: 1.56 ± 0.053 nM) after treatment with IL-
6 compared to vehicle treated cells (p < 0.05, Figure 7A). There was no effect on the levels of 
kynurenine at any time point (Figure 7B). 
 
Figure 7. Kynurenic acid (KYNA) (A) and kynurenine (KYN) (B) levels (mean ± SEM) in cell 
media from cultured astrocytes treated with interleukin (IL)-6 or vehicle. Media was collected after 
24, 48, and 72 h post-treatment. * = p < 0.05, one-way ANOVA with Bonferroni corrections versus 
vehicle within each time point. 
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4.3 PAPER III 
In paper III, the functional effects of GRK3 gene deletion were studied in mice using relevant 
behavioral paradigms for schizophrenia. Further, effects of allelic variants of GRK3 on CSF 
KYNA in healthy controls and on the history of psychosis in bipolar disorder patients were 
explored. 
4.3.1 Identification of SNPs associated with schizophrenia 
The Psychiatric Genetic Consortium (PGC) database was searched for single nucleotide 
polymorphisms (SNPs) in proximity to the GRK3 gene. Here, the SNP with the strongest 
association to the schizophrenia phenotype (rs478655, OR = 0.91, MAF = 0.29, p = 4.8 × 10-4), 
located within the promoter region of GRK3, was further analyzed with regard to expression. In 
the HapMap2 database, the minor T allele of rs478655 was associated with increased GRK3 
expression (additive model; β = 0.051, p = 0.026, mean T/T (n = 31) = 7.712, T/C (n = 104) = 
7.584, C/C (n = 112) = 7.575). 
 
In order to investigate the functional allele effect with regard to psychotic disorders, the rs478655 
allele effect on KYNA levels was tested in a genotyped cohort of healthy individuals. This was 
performed as KYNA previously have been shown to be associated with psychosis (see 1.3; 
Kynurenic acid and schizophrenia). Here, the T/T haplotype, which was associated with 
increased GRK3 expression in the HapMap2 database, was associated with decreased levels of 
CSF KYNA (β = -0.33, p = 0.041, Figure 8A). Additional support for allele association with 
psychosis was revealed when the bipolar patients were stratified by history of psychosis. The 
minor T allele was here shown to be associated with decreased risk for psychosis (OR = 0.39, 
MAF = 0.33, p = 0.03, Figure 8B). 
Figure 8. (A) Cerebrospinal fluid (CSF) levels of kynurenic acid between rs47655 haplotypes (β 
= -0.33, p = 0.041). (B) T/T haplotype frequency in bipolar patients stratified by history of 
psychosis (OR = 0.39, MAF = 0.33, p = 0.03). 
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4.3.2 P2X7 membrane levels in Grk3-/- mice 
The assumed disrupted P2X7 internalization process by GRK3 loss-of-function was studied in 
Grk3-/- mice. Here, P2X7 internalization was investigated by separating whole-brain derived cell 
homogenate into subcellular and plasma membrane fractions. P2X7 levels were thereafter 
determined by western blot and normalized to β-actin. Grk3-/- animals displayed significantly 
decreased P2X7 levels in internal membrane fractions compared to Grk3+/+ littermates (Grk3-/-: 
0.87 ± 0.091, n = 5; Grk3+/+: 1.73 ± 0.43, n = 6, p = 0.017, Figure 9B). Plasma membrane levels 
of P2X7 were higher in Grk3-/- mice but did not reach statistical significance (Figure 9A). 
 
4.3.3 Hippocampal IL-1β levels in Grk3-/- mice 
P2X7-induced caspase activation is a key mediator to subsequent IL-1β release (see 1.2.2; The 
P2X7 receptor. Experiments were thereafter carried out to investigate whether the disrupted 
P2X7 internalization seen in Grk3-/- gave rise to increased IL-1β levels. Drug-naïve Grk3-/- mice 
were euthanized and IL-1β levels in hippocampal tissue was measured by chemoluminescence 
(Meso scale). The levels of IL-1β were found to be significantly higher in Grk3-/- mice (0.76 ± 
0.093 pg/ml, n = 5) compared to Grk3+/+ animals (0.37 ± 0.066 pg/ml, n = 5, p = 0.008, Figure 
10). 
4.3.4 ICV IL-1β administration in C57BL6 mice 
 In agreement with previous unpublished data showing that IL-1β induces TDO and increases 
astrocyte KYNA production (Sellgren et al., 2015), brains from C57BL6 mice contained 
significantly higher levels of KYNA after ICV IL-1β. Mice were sacrificed six hours post-
injection (IL-1β: 9.46 ± 1.88 nM, n = 7, versus vehicle: 3.50 ± 0.49 nM, n = 8, p < 0.001, Figure 
11).  
Figure 9. P2X7 levels in plasma membrane fractions (A) and internal membrane fractions (B) 
from Grk3-/- (n = 6) mice whole-brain compared to Grk3+/+ littermates (n = 5). Data are mean 
± SEM. * = p < 0.05 (Mann-Whitney) 
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The increase seen here at the 0.5 ng dose, but not at higher doses may be explained by KMO and 
/ or kynureninase activation (see 1.3.1; The kynurenine pathway, and Zunszain et al., 2012) at 
doses above 0.5 ng. In addition, the effects of IL-1β on hippocampal dependent memory appears 
follow an inverted U-shape pattern (Goshen et al., 2007). 
4.3.5 PPI 
4.3.5.1 Grk3-/- mice 
In the variable prepulse intensity block, Grk3-/- mice displayed decreased PPI as evident by a 
significant genotype × prepulse intensity interaction (F (2, 74) = 4.20, p < 0.05). Post-hoc 
comparisons further revealed significantly lower % PPI in Grk3-/- mice at the 73 dB prepulse 
level (eight dB over background) compared to Grk3+/+ littermates (Grk3-/-: 36.87 ± 5.17, n = 19, 
versus Grk3+/+: 50.44 ± 3.56, n = 20, p < 0.05, Figure 12B). There was no difference between 
genotypes in basal startle magnitude (Figure 12A), nor in the variable interstimulus interval 
block (data not shown). 
 
Figure 10 
 
Figure 11 
Figure 10. Hippocampal Interleukin (IL)-1β levels in Grk3-/- (n = 5) mice compared to Grk3+/+ littermates 
(n = 5). Bars are mean ± SEM. ** = p < 0.01 (Mann-Whitney). Figure 11. Kynurenic acid (KYNA) levels in 
whole-brain from C57BL6 mice administered IL-1β intracerebroventricular (ICV) in escalating doses (n = 6 
– 8). *** = p < 0.001 (One-way ANOVA with Bonferroni corrections). 
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4.3.5.2 ICV IL-1β administration 
In similarity to the Grk3-/- mice, a low dose of ICV administered IL-1β decreased PPI across 
hours 1 – 3 post-infusion in C57BL6 mice (0.5 ng: 22.06 ± 4.24 nM versus vehicle: 38.31 ± 5.57, 
p < 0.05, Bonferroni's post-hoc, Figure 13A). Throughout the six h session there was a 
significant decrease in % PPI in mice administered 0.5 ng IL-1β (main effect of drug, p = 0.0345, 
Figure 13B). 
 
Figure 12. Average (± SEM) startle magnitude (A) and percent prepulse inhibition (PPI, B) in 
Grk3-/- mice (n = 19) compared to Grk3+/+ littermates (n = 20). (A) Startle magnitude was 120 dB 
and (B) prepulses 69, 73, and 81 dB, after which a single 120 dB pulse followed. # = p < 0.05, 
two-way repeated measures ANOVA (genotype × prepulse level). * = p < 0.05, Tukey´s post-hoc 
test. 
Figure 13. (A) Average (± SEM) percent prepulse inhibition (PPI) in C57BL6 mice receiving interleukin 
(IL)-1β intracerebroventricular (ICV). Data are collapsed across hour 1 – 3 post infusion. (B) Average (± 
SEM) percent PPI in mice receiving 0.5 ng IL-1β tested hourly over 6 h. * = p < 0.05, two-way repeated 
measures ANOVA (treatment × prepulse level) with Tukey corrections. 
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4.3.6 Microdialysis 
4.3.6.1 Probenecid administration in Grk3-/- mice 
As IL-1β induces the kynurenine pathway in vitro (see 1.3.2; Regulation of the kynurenine 
pathway) and in vivo (see 4.3.4; ICV IL-1β administration in C57BL6 mice), Grk3-/- mice brains 
were analyzed with regard to kynurenine and KYNA content. Here, Grk3-/- mice display higher 
basal hippocampal levels of kynurenine versus Grk3+/+ mice (115.2 ± 5.74 nM, n = 7, versus 
96.19 ± 3.3 nM, n = 8, p = 0.0140). Further, no difference in basal KYNA level between 
genotypes was found (data not shown). However, when inhibiting brain KYNA efflux by 
probenecid (200 mg/kg, i.p.), there was a significantly higher KYNA accumulation in Grk3-/- 
mice compared to Grk3+/+ littermates as measured by microdialysis (Figure 14A). 
4.3.6.2 Amphetamine administration in Grk3-/- mice 
Patients with schizophrenia display increased dopamine release in response to amphetamine 
compared to healthy controls (see 1.5; The dopamine and glutamate hypothesis). Difference in 
amphetamine responsiveness between Grk3-/- and Grk3+/+ mice was here investigated my means 
of microdialysis. In this setting, Grk3-/- mice displayed increased striatal dopamine compared to 
Grk3+/+ littermates (Figure 14B). 
4.3.7 Immunohistochemistry 
Staining for the astrocytic marker GFAP revealed significantly higher immunoreactivity in   
Grk3-/- mice compared to Grk3+/+ animals in the hippocampus (≈ bregma -1.46, p = 0.037, 
Figure 15 top panel), cerebral peduncle (p = 0.037, Figure 15 middle panel), thalamus (p = 
0.005, Figure 15 bottom panel), and paraventricular hypothalamus (p = 0.044, not shown). 
Staining for the microglial markers ionized calcium binding adaptor molecule (Iba)-1 or cluster of 
differentiation molecule (CD)11b showed no difference between genotypes (data not shown), 
collectively indicating a specific elevated astrocytic immunoreactivity in Grk3-/- mice. 
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Figure 14. Change in hippocampal kynurenic acid (KYNA, A) and striatal dopamine (DA, B) after i.p. 
administration of (A) probenecid or (B) amphetamine to Grk3-/- mice (A, B, n = 5) versus Grk3+/+ 
littermates (A, n = 6, B, n = 5). Datapoints are mean ± SEM percent change versus pre-drug value. 
**** = p < 0.0001, *** = p < 0.001, ** = p < 0.01, * = p < 0.05, one-way repeated measures ANOVA 
with following Bonferroni corrections compared to pre-drug value. +++ = p < 0.001, ++ = p < 0.01, + 
= p < 0.05, two-way repeated measures ANOVA (genotype × time) with Bonferroni corrected 
comparisons between genotypes. 
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Figure 15. GFAP stained hippocampus (D3V = dorsal third ventricle, top panel), cerebral 
peduncle (cp, middle panel), and thalamus (Rt = Reticular, LD = laterodorsal, VP = ventral 
posterior, bottom panel). (A, Grk3-/- B, Grk3+/+). Scalebar = 200 µm 
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4.4 PAPER IV 
The effects of single and dual injections of LPS (0.83 mg/kg per injection) were investigated with 
regard to central and peripheral levels of kynurenines, dopamine, and 5-HT with their respective 
metabolites. Results showed that dual, but not single LPS injections affected brain and serum 
levels of KYNA, brain QUIN (Figure 16 C, D, E, F), and serum tryptophan (Figure 16 H). The 
effect on KYNA seem to be regimen-dependent as no dose-response pattern was seen and mice 
receiving a single 1.66 mg/kg LPS injection did not display elevated brain KYNA (data not 
shown). Brain and serum kynurenine and brain tryptophan were affected by both LPS regimens 
(Figure 16 A, G, B). 
Indications of increased brain IDO and/or TDO activity was present at all time points after dual 
LPS as reflected by an increased kynurenine:tryptophan ratio. A single LPS injection increased 
the kynurenine:tryptophan ratio at time points, 24 and 120 hours (data not shown). 
Brain dopamine and 5-HT was unaffected by both treatment regimens (data not shown. However, 
turnover was affected as evident by increased HVA:dopamine, and 5-HIAA:5-HT ratio at the 24 
and 48 hour timepoint by dual LPS injections, and at 24 hours by single LPS. 
Data show that the response to LPS with respect to kynurenines is altered depending on injection 
regimen. Here, only dual LPS elevated brain KYNA and QUIN. The effects seen here may have 
numerous causes such as facilitated passage of peripheral cytokines or kynurenine across the 
BBB induced by LPS. LPS induces BBB permeability (Jangula and Murphy, 2013) while only 
entering the brain in trace amounts (Banks and Robinson, 2010). In addition, LPS induces 
cytokine release from endothelial cells lining the BBB (Reyes et al., 1999) and facilitates BBB 
adhesion and transport of immune cells (de Vries et al., 1994; Persidsky et al., 1997). 
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Figure 16. Levels (mean ± SEM) of kynurenine (A, B), kynurenic acid (KYNA C, 
D), quinolinic acid (QUIN E, F), and tryptophan (G, H) in the brain (A, C, E, G) 
and serum (B, D, F, H) in mice receiving single (grey bars) and dual (black bars) 
LPS (0.83 mg/kg/injection) injections. **** = p < 0.0001, *** = p < 0.001, ** = p < 
0.01, * = p < 0.05, versus controls (white bars). + = p < 0.05, versus single LPS. 
Kruskal Wallis with Dunn corrections. n = 6 – 8 in each group. 
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5 GENERAL DISCUSSION 
Data presented in this thesis suggest that GRK3 is as a putative contributor to psychosis. Thus, 
GRK3 expression was found to associate with CSF KYNA levels and with psychosis in patients 
with bipolar disorder. GRK3 participates in inflammatory signaling by inhibiting P2X7 
dependent IL-1β activation (Figure 17). Loss of function in GRK3 would consequently lead to 
increased immune signaling. Testing for such consequences was therefore carried out in Grk3-/- 
mice. 
In Grk3-/- mice, signs of decreased P2X7 internalization were seen. This decrease would 
hypothetically lead to excess caspase-1 stimulation, causing increased IL-1β release. Indeed, 
measurements of hippocampal IL-1β in Grk3-/- mice were in line with this. 
Building from previous data showing that IL-1β induce KYNA levels in astrocytes (Sellgren et 
al., 2015), C57BL6 mice here ICV injected with IL-1β displayed increased levels of brain 
KYNA. In addition, it was demonstrated that the induction of brain KYNA by LPS is treatment 
regimen dependent. While a single injection of LPS did not influence brain KYNA, mice 
receiving dual injections displayed marked elevations. The reasons for these disparate changes in 
KYNA are yet unknown but may include increased permeability of the BBB to peripheral 
kynurenines and cytokines. 
 
Figure 17. GRK3 Loss of function leading to increased activation of the kynurenine pathway via IL-
1β. Activation of the kynurenine pathway is suggested to induce symptoms associated with 
psychotic disorders, including schizophrenia. 
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Testing for a schizophrenia-like phenotype in Grk3-/- mice revealed deficits in PPI, possibly 
related to the increased turnover of KYNA, as elevated levels of KYNA have previously been 
shown to induce such deficits (Erhardt et al., 2004), and that ICV administration of IL-1β 
increase KYNA and cause similar reduction in PPI. Furthermore, Grk3-/- mice display elevated 
hippocampal kynurenine levels in addition to the increased KYNA turnover.  
The connection previously shown between KYNA and dopamine was further strengthened as 
Grk3-/-, and mice with subchronically elevated brain KYNA levels showed an augmented 
response to amphetamine. This was verified by increased striatal dopamine release (Grk3-/-) and 
increased locomotor activity in mice with elevated KYNA. These results provide a functional link 
between the abundant evidence on dopaminergic dysfunction and elevated KYNA in 
schizophrenia. 
In addition, patients with schizophrenia displayed increased CSF levels of IL-6, further 
strengthening the hypothesis of immune activation in schizophrenia. In addition, an intimate 
relationship between IL-6 and the schizophrenia-linked kynurenine pathway is suggested based 
on the correlations found in patients, and the KYNA inducing properties of IL-6 in astrocytes. 
Interestingly, only IL-6 was found to be elevated in these chronic patients, in contrast to the 
selective increase of IL-1β previously shown in first-episode patients (Söderlund et al., 2009). 
Collectively, thesis data demonstrate that mice with subchronically elevated levels of KYNA, or 
lacking GRK3 display multiple functional deficits further underlining the involvement of KYNA 
and inflammatory signaling in the pathophysiology of schizophrenia. 
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